Stiefel Laboratories, Inc. Successfully Completes Tender Offer for Shares of Barrier...

Stiefel Laboratories, Inc. Successfully Completes Tender Offer for Shares of
Barrier Therapeutics, Inc.

CORAL GABLES, Fla., Aug. 5 /PRNewswire/ -- Stiefel Laboratories, Inc.
("Stiefel Laboratories"), the world's largest independent pharmaceutical
company specializing in dermatology, announced today that its wholly owned
subsidiary, Bengal Acquisition Inc., has completed its all cash tender offer
for the outstanding shares of common stock of Barrier Therapeutics, Inc.
("Barrier Therapeutics") (Nasdaq: BTRX). The tender offer expired, as
scheduled, at 12:00 midnight, New York City time, on Monday August 4, 2008.
The depositary for the tender offer has advised us that, as of the
expiration of the tender offer, an aggregate of 34,266,494 shares of Barrier
Therapeutics common stock (including 621,093 shares that were tendered
pursuant to the guaranteed delivery procedures) have been tendered into, and
not properly withdrawn from, the tender offer. The tendered shares represent
approximately 97% of the outstanding shares of Barrier Therapeutics common
stock as of August 5, 2008. All of such shares have been accepted in
accordance with the terms of the tender offer and, upon Stiefel Laboratories'
acquisition of such shares, Barrier Therapeutics will become a majority owned
indirect subsidiary of Stiefel Laboratories.
Pursuant to the terms of the previously announced Merger Agreement, dated
as of June 23, 2008, by and among Stiefel Laboratories, Bengal Acquisition
Inc. and Barrier Therapeutics, Stiefel Laboratories and Bengal Acquisition
Inc. expect to effect a merger of Bengal Acquisition Inc. with and into
Barrier Therapeutics, with Barrier Therapeutics continuing as the surviving
corporation following the merger. Upon the effectiveness of the merger, each
outstanding share of Barrier Therapeutics common stock will be converted into
the right to receive the same $4.15 per share in cash, without interest and
less any required withholding taxes, if any, that will be paid to the holders
of shares of common stock that were tendered in the tender offer. As a result
of the merger, Barrier Therapeutics will become a wholly owned subsidiary of
Stiefel Laboratories and Barrier Therapeutics' common stock will be delisted
from and will cease to trade on the NASDAQ Global Market. Stiefel
Laboratories, Bengal Acquisition Inc. and Barrier Therapeutics intend to
complete the merger as soon as practicable following the satisfaction of the
conditions in the Merger Agreement.
About Stiefel Laboratories, Inc.
Founded in 1847, Stiefel Laboratories (a privately held company) is the
world's largest independent pharmaceutical company specializing in
dermatology. The company manufactures and markets a variety of prescription
and non-prescription dermatological products. Some of the newest and best-
known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide,
5%) available in the Duac(R) Care System (CS); Evoclin(R) (clindamycin
phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R)
Cream; Olux(R) (clobetasol propionate) Foam, 0.05% and Olux-E(R) (clobetasol
propionate) Foam, 0.05% also available in the Olux(R) / Olux-E(R) COMPLETE
PACK; Soriatane(R) (acitretin) Capsules available in the Soriatane(R) CK
CONVENIENCE KIT; Verdeso(R) (desonide) Foam, 0.05%; Brevoxyl(R)-4 Creamy Wash
(benzoyl peroxide 4%) and Brevoxyl(R)-8 Creamy Wash (benzoyl peroxide 8%)
packaged in the Brevoxyl(R) Acne Wash Kit; Extina(R) (ketoconazole) Foam, 2%;
Oilatum(R) Cleansing Bar; Physiogel(R) Cream; Stieprox(R) (ciclopirox olamine)
Shampoo; REVALESKIN(TM) Skin Care Products; and Sarna(R) Lotion. Its wholly-
owned global network is comprised of more than 30 subsidiaries, manufacturing
plants in six countries, research and development facilities on four
continents, and products marketed in more than 100 countries around the world.
Stiefel Laboratories supplements its R&D efforts by seeking strategic
partnerships and acquisitions around the world. To learn more about Stiefel
Laboratories, Inc. visit www.stiefel.com .
About Barrier Therapeutics
Barrier Therapeutics is a pharmaceutical company focused on the
development and commercialization of products in the field of dermatology.
Barrier Therapeutics currently markets three pharmaceutical products in the
United States: Xolegel(R) (ketoconazole, USP) Gel, 2%, for seborrheic
dermatitis; Vusion(R) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white
petrolatum) Ointment, for diaper dermatitis complicated by documented
candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution,
for solar lentigines. Barrier Therapeutics has other product candidates in
various stages of clinical development for the treatment of a range of
dermatological conditions, including onychomycosis, psoriasis, acne, skin
allergies, and acute fungal infections. The company is headquartered in
Princeton, New Jersey and has a wholly-owned subsidiary in Geel, Belgium.
More information about Barrier Therapeutics can be found on its corporate
website at: www.barriertherapeutics.com .
Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics.
Important Information About the Tender Offer
This announcement and the description contained herein are for
informational purposes only and are not an offer to purchase or a solicitation
of an offer to sell securities of Barrier Therapeutics. Stiefel Laboratories
and Bengal Acquisition Inc. have filed with the SEC a tender offer statement
on Schedule TO containing an offer to purchase, forms of letters of
transmittal and other documents relating to the offer, and Barrier
Therapeutics has filed with the SEC a solicitation/recommendation statement on
Schedule 14D-9, with respect to the offer. These documents contain important
information about the tender offer and the proposed merger. Stockholders of
Barrier Therapeutics are urged to read them carefully. Stockholders can
obtain these documents free of charge from the SEC's website at www.sec.gov or
by contacting the Information Agent for the offer, Mellon Investor Services
LLC, at (201) 680-5235 or (877) 892-8805 (toll-free).
SOURCE Stiefel Laboratories, Inc.

Erin Bacher, Associate Director, Global Public Relations, +1-678-889-4039,
erin.bacher@stiefel.com, Amy Button, Associate Manager, Global Public
Relations, +1-678-714-4153, amy.button@stiefel.com, both of Stiefel
Laboratories, Inc.